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ABSTRACT: Little is known about survival and clinical prognostic factors in females with chronic
obstructive pulmonary disease (COPD). The aim of the present study was to determine the
survival difference between males and females with COPD and to compare the value of the
different prognostic factors for the disease.
In total, 265 females and 272 males with COPD matched at baseline by BODE (body mass index,
airflow obstruction, dyspnoea, exercise capacity) and American Thoracic Society/European
Respiratory Society/Global Initiative of Chronic Obstructive Lung Disease criteria were
prospectively followed. Demographics, lung function, St George’s Respiratory Questionnaire,
BODE index, the components of the BODE index and comorbidity were determined. Survival was
documented and sex differences were determined using Kaplan–Meier analysis. The strength of
the association of the studied variables with mortality was determined using multivariate and
receiver operating curves analysis.
All-cause (40 versus 18%) and respiratory mortality (24 versus 10%) were higher in males than
females. Multivariate analysis identified the BODE index in females and the BODE index and
Charlson comorbidity score in males as the best predictors of mortality. The area under the curve
of the BODE index was a better predictor of mortality than the forced expiratory volume in one
second for both sexes.
At similar chronic obstructive pulmonary disease severity by BODE index and forced expiratory
volume in one second, females have significantly better survival than males. For both sexes the
BODE index is a better predictor of survival than the forced expiratory volume in one second.
KEYWORDS: BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index,
chronic obstructive pulmonary disease, mortality, sex
T
here is increasing evidence supporting sex
differences in the clinical expression of
chronic obstructive pulmonary disease
(COPD). Females seem to be more susceptible
to the toxic effects of tobacco than males [1–5],
They also report more anxiety and depression [6,
7], worse symptoms [8–10], lower exercise cap-
acity [11], more airway hyperresponsiveness [12]
and worse health-related quality of life (HRQoL)
[8, 11, 13, 14] than males. In a recent study by
MARTINEZ et al. [8], females with severe emphy-
sema enrolling in the National Emphysema
Treatment Trial, smoked less, had a worse
modified BODE (body mass index, airflow
obstruction, dyspnoea, exercise capacity) index
and lower diffusing capacity of the lung for
carbon monoxide than their male counterparts.
The pathological lung specimens of females
exhibited smaller airway lumens with dispropor-
tionately thicker airway walls, less extensive
emphysema characterised by smaller hole size
and less peripheral involvement than those of
males. The same results were also produced by
DRANSFIELD et al. [15].
Whether or not the clinical differences in the
expression of COPD in females result in different
all-cause and respiratory mortality compared to
those of males remains unknown. The limited
available information about sex differences in
COPD mortality is derived from studies of
patients with advanced stages of disease and
hypoxaemic respiratory insufficiency [16–19].
In the present study, the authors tested the
hypothesis that females with similar degrees of
COPD severity (determined by the BODE index
and percentage forced expiratory volume in one
second (FEV1%)) have a different survival than
males in a cohort of COPD patients with a wide
range of airway obstruction from five countries
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(USA, Spain, Chile, Venezuela and Uruguay). In addition, the
strength of the association between the baseline variables and
mortality in the two sexes was also tested.
METHODS
Patients
In total, 265 females with a wide range of COPD severity,
according to the American Thoracic Society (ATS), European
Respiratory Society (ERS) [20] and the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria [21], were
sequentially recruited into the BODE observational study
between January 1997 and September 2006, at several clinics
in the USA (Boston, MA and Bay Pines, FL), Venezuela, Chile,
Uruguay and Spain (Tenerife, Pamplona and Zaragoza). As
originally described, the BODE study [22] prospectively
enrolled a cohort of well phenotyped patients with COPD
irrespective of sex. Initially, few females were enrolled but
over time more participated. Once an appropriate number of
female patients followed for o1 yr had been achieved, the
current authors decided to retrospectively analyse the presence
of sex differences in outcome. A total of 272 males from the
same BODE cohort were matched by region and similar stage
of COPD severity by BODE and ATS/ERS/GOLD criteria.
Special attention was given to include individuals enrolled
during the same study period to avoid treatment differences
over time. For example, if a female COPD patient was enrolled
in June 2000, a male COPD patient with similar FEV1% and
BODE index enrolled during the same year and region was
selected for the matching process. The matched patients were
obtained from an initial sample of 1,115 males and 269 females
with COPD. Every female could be matched with a male with
an FEV1 of ¡5% predicted and similar BODE index. To avoid
selection bias, when more than one male was matched and
they had a different BODE index, the present authors decided
to include both male patients with the same FEV1; this event
occurred in seven patients. The four female patients who had
no match were not included in the analysis. Inclusion and
exclusion of these 11 patients do not affect the results. Partici-
pants were receiving standard medical treatment according to
the ATS/ERS consensus [20]. The human research-review
board at each site approved the study and all patients signed
the informed consent. The inclusion/exclusion criteria have
been previously published [22]. Briefly, COPD was defined by
a history of smoking o10 pack-yrs and a FEV1/forced vital
capacity ratio ,0.7 measured 20 min after the administration
of 400 mg of inhaled albuterol. Patients were excluded if they
had a history of asthma, bronchiectasis, tuberculosis or other
confounding diseases, such as congestive heart failure, obliter-
ative bronchiolitis or diffuse panbronchiolitis. The patients
completed evaluation within 6 weeks of enrolment and con-
tinued to be followed thereafter until August 2007 or until death.
The patient and their family were contacted if the patient failed
to return for appointments. Death from any cause and from
specific respiratory causes was recorded. The investigators at
each site determined the cause of death after reviewing the
medical record and death certificate. The cause of death was
classified as respiratory (if it was due to COPD, respiratory
failure or respiratory tract infection), cardiovascular, lung cancer
or others.
Measurements
Demographic and anthropometric information was collected.
Spirometry, lung volumes and the 6-min walking distance
(6MWD) were performed following ATS guidelines [23, 24].
TABLE 1 Baseline characteristics of patients in the cohort
Variables Male Female p-value#
Subjects n 272 265
Age yrs 67¡8 63¡10 ,0.001
Current smoking % 32 44 0.005
Tobacco use pack?yr-1 81¡43 51¡29 ,0.001
Charlson’s index points 3.8¡2.6 2.7¡2.4 ,0.001
BODE index points 3.49¡2.5 3.37¡2.1 0.55
MMRC points 2.0¡1.1 2.11¡0.9 0.5
6MWD m 392¡138 392¡103 0.9
BMI kg?m-2 26.8¡5 25.7¡5 ,0.01
FEV1 % pred 49¡20 50¡19 0.87
FVC % pred 74¡22 78.7¡23 0.05
FEV1/FVC % 46¡13 48.8¡12 0.06
IC/TLC % 32¡1 30¡1 0.05
SGRQ total 44¡21 48¡19 0.04
Data are presented as mean¡SD, unless otherwise stated. BODE: body mass
index (BMI), airflow obstruction, dyspnoea, exercise capacity; MMRC: modified
Medical Research Council dyspnoea scale; 6MWD: 6-min walk distance; FEV1:
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity; IC: inspiratory capacity; TLC: total lung capacity; SGRQ: St George’s
Respiratory Questionnaire. #: comparison between males and females.
TABLE 2 Baseline characteristics of male and female
patients who died from any cause during the
study period
Variables Male Female p-value#
Subjects n 97 44
Age yrs 70¡8 68¡8 0.19
Current smoking % 30 35 0.64
Tobacco use pack?yr-1 90¡38 70¡40 ,0.001
Charlson’s index points 4.75¡2.9 3.8¡2.6 0.08
BODE index points 4.9¡2.6 5¡1.7 0.69
MMRC points 2.64¡0.9 2.48¡0.8 0.34
6MWD m 305¡135 292¡108 0.58
BMI kg?m-2 26¡5 23.7¡5 0.03
FEV1 % pred 44¡19 39¡14 0.16
FVC % pred 67¡19 69¡21 0.61
FEV1/FVC % 44¡13 44¡13 0.99
IC/TLC % 28¡1 27¡1 0.40
SGRQ total 52¡19 58¡16 0.11
Data are presented as mean¡SD, unless otherwise stated. BODE: body mass
index (BMI), airflow obstruction, dyspnoea, exercise capacity; MMRC: modified
Medical Research Council dyspnoea scale; 6MWD: 6-min walk distance; FEV1:
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity; IC: inspiratory capacity; TLC: total lung capacity; SGRQ: St George’s
Respiratory Questionnaire. #: comparison between males and females.
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Dyspnoea was assessed using the modified Medical Research
Council dyspnoea scale (MMRC) [25]. The body mass index
(BMI) was calculated as the weight in kg divided by height in
m2. The presence of comorbidities was evaluated using the
Charlson scale [26], where points are assigned to the presence
of different comorbidities. The score ranges from 0–37, with the
higher the score implying more comorbidities. Smoking status
was expressed in pack-yrs. Inspiratory capacity (IC) was
measured as previously described and IC/total lung capacity
(TLC) was determined from the lung volume measurements
[27]. The BODE index was measured and staged in quartiles as
previously published [22]. In short, the BODE index is a
multidimensional grading system integrated by four variables:
BMI (B); airflow obstruction (O), as measured by the post-
bronchodilator FEV1 % pred; dyspnoea (D), assessed by the
MMRC score; and exercise tolerance (E) measured by 6MWD.
The variables were graded from 0–3 (0 or 1 for BMI) and added
to provide a total score ranging 0–10. A higher score indicates a
greater risk of death and one point increase in the index
represents a 34% and 62% increase in global and respiratory
mortality, respectively. The St George’s Respiratory Question-
naire (SGRQ) was used to determine HRQoL [28] with the
higher the index the greater health impairment and with four
points representing a clinical significant difference [29].
Statistical analysis
Quantitative data with a normal distribution was presented as
mean¡SD. Qualitative data was described using relative
frequencies. Survival times with all-cause and respiratory
mortality were determined. Differences between female and
male deceased patients were assessed using paired t-tests for
independent sample or Pearson Chi-squared test, depending
on variable characteristics. Kaplan–Meier analysis was used for
comparison survival between males and females with similar
COPD severity (BODE index and FEV1%). The statistical
significance was evaluated using the log-rank test. Cox
proportional hazard ratio analysis was performed to determine
the best predictors of mortality in each sex, adjusting for
factors that showed differences between males and females:
age, pack-yrs, comorbidity and BMI. In the analysis all factors
that have been shown to predict mortality in COPD patients
were included: FEV1%; 6MWD; MMRC; IC/TLC and the
BODE index. To determine the relative predictive value for
mortality of the BODE index compared with the FEV1%, C
statistics were computed for a model containing FEV1 or the
BODE score as the sole independent variable. In these
analyses, the C statistic is a mathematical function of the
sensitivity and specificity of the BODE index and FEV1% in
classifying patients by means of the Cox model as either dying
or surviving. The null value for the C statistic is 0.5, with a
maximum of 1.0; the higher the area under the curve, the better
the predictive power. Significant levels for all tests were
established as two-tailed p-value f0.05.
TABLE 3 Baseline characteristics of male and female
patients who died from respiratory causes during
the study period
Variables Male Female p-value#
Subjects n 55 21
Age yrs 68¡8 67¡9 0.88
Current smoking % 57 32 0.05
Tobacco use pack?yr-1 86¡41 69¡40 0.86
Charlson’s index points 4.8¡3 4.0¡2 0.81
BODE index points 5.0¡2.7 5.1¡1.7 0.86
MMRC points 2.8¡0.9 2.5¡0.8 0.96
6MWD m 300¡139 285¡115 0.14
BMI kg?m-2 26¡6 23.5¡5 0.08
FEV1 % pred 42¡18 39¡14 0.08
FVC % pred 73¡23 67¡19 0.93
FEV1/FVC % 43¡13 42¡13 0.86
IC/TLC % 28¡12 27¡9 0.38
SGRQ total 55¡21 58¡15 0.47
Data are presented as mean¡SD, unless otherwise stated. BODE: body mass
index (BMI), airflow obstruction, dyspnoea, exercise capacity; MMRC: modified
Medical Research Council dyspnoea scale; 6MWD: 6-min walk distance; FEV1:
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity; IC: inspiratory capacity; TLC: total lung capacity; SGRQ: St George’s
Respiratory Questionnaire. #: comparison between males and females.
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FIGURE 1. a) All-cause mortality and b) respiratory mortality represented by
the four BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity)
quartiles. Significant differences were found in all quartiles for all-cause mortality
and in Q4 for respiratory mortality. The number of female and male, respectively, all-
cause or respiratory mortality patients in each quartile was as follows. Q1: 85 and
97; Q2: 85 and 90; Q3: 56 and 46; Q4: 39 and 39.h: females; &: males. *: p,0.05.
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RESULTS
The baseline characteristics of the study patients by sex are
shown in table 1.
A similar number of males and females were recruited at all
sites and there were no differences in any of the variables
among regions (data not shown); therefore, the data is pres-
ented as a group. A total of 265 females and 272 males with
COPD were included in the study. The patients were followed
for a mean of 49¡28 months. FEV1% ranged between 10 and
94% of predicted value. According to ATS/ERS/GOLD
criteria, there were 14% COPD patients in stage I, 31% in
stage II, 37% in stage III and 18% in stage IV. Conversely, 36%
were in BODE Q1, 33% in Q2, 19% in Q3 and 12% in Q4.
Table 1 shows that at similar degree of airflow obstruction,
there were differences between males and females in age,
smoking status, pack-yrs history, comorbidity, BMI and SGRQ.
Mortality
A total of 141 (26.2%) patients died during the follow-up
period. The mean follow-up time from enrolment to death was
34¡21, 39¡22 and 32¡20 months for the group, females and
males, respectively. A total of 97 patients (69% of the
nonsurvivors) were male. In total, 76 (54%) patients died due
to respiratory causes during the study period. Mortality at each
centre was higher in males than in females.
The characteristics of nonsurvivor male and female patients
are shown in tables 2 and 3. For all-cause mortality, non-
survivor females were very similar to males except for a lower
BMI and lower tobacco consumption in pack-yrs. The BODE
and the Charlson comorbidity indexes were similar in both
sexes (table 2). Survivors and nonsurvivors were similar in all
parameters for respiratory deaths (table 3).
Figure 1 shows all-cause and respiratory mortality in non-
survivor males and females by BODE quartiles. Females had
significantly lower all-cause mortality than males in all
quartiles. Respiratory mortality was similar in all BODE
quartiles except Q4 where it was higher in males.
The Kaplan–Meier analysis (fig. 2) showed that survival was
significantly higher in females than males with similar BODE
index and FEV1 (p,0.001).
Univariate and multivariate analysis
The predictive power for all-cause and respiratory mortality of
the variables selected, adjusted for age, pack-yrs history,
Charlson and BMI are shown in tables 4 and 5. Table 4 shows
the results of the univariate analysis, whereas table 5 shows
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FIGURE 2. Kaplan–Meier survival curves of the study population by sex. Log
rank analysis shows that survival is better for the female (83%) than the male (67%)
population. ????????: females; –––––: males. The number of females at 0, 12, 24, 36,
48, 60, 72, 84 and 96 months follow-up were 265, 257, 249, 245, 237, 228, 232, 222
and 220, respectively. The number of males at 0, 12, 24, 36, 48, 60, 72, 84 and 96
months follow-up were 272, 257, 235, 221, 198, 191, 186, 185 and 183, respec-
tively. Chi-squared: 19.3. Log rank analysis: p,0.001.
TABLE 4 Cox proportional hazard ratio univariate analysis
to investigate the predictive power for mortality of
each of the selected variables in male and
female patients with chronic obstructive
pulmonary disease#
Outcome and variable HR 95% CI p-value
All-cause mortality
FEV1 %
Males 0.98 0.97–0.99 0.01
Females 0.93 0.90–0.97 ,0.001
6MWD
Males 0.99 0.98–0.99 ,0.001
Females 0.99 0.98–0.99 ,0.001
MMRC
Males 1.89 1.50–2.38 ,0.001
Females 2.11 1.17–3.79 0.01
IC/TLC
Males 0.01 0.002–0.20 0.001
Females 0.91 0.83–0.99 0.04
BODE
Males 1.30 1.27–1.46 ,0.001
Females 1.65 1.31–2.07 ,0.001
Respiratory mortality
FEV1 %
Males 0.98 0.96–0.99 0.01
Females 0.99 0.98–0.99 ,0.001
6MWD
Males 0.99 0.98–0.99 ,0.001
Females 0.99 0.98–0.99 ,0.001
MMRC
Males 2.24 1.68–2.97 ,0.001
Females 2.48 1.32–4.68 0.005
IC/TLC
Males 0.01 0.01–0.31 0.006
Females 0.01 0.00–0.77 0.04
BODE
Males 1.35 1.21–1.50 ,0.001
Females 1.74 1.36–2.23 ,0.001
HR: hazard ratio; CI: confidence interval; FEV1: forced expiratory volume in one
second; 6MWD: 6-min walk distance; MMRC: modified Medical Research
Council dyspnoea scale; IC: inspiratory capacity; TLC: total lung capacity;
BODE: body mass index (BMI), airflow obstruction, dyspnoea, exercise
capacity. #: analysis adjusted for age, pack-yrs history, comorbidity and BMI.
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the final result of the multivariate analysis, which included all
factors that showed significance in the univariate analysis
again adjusted for the same parameters. The BODE index was
the only variable associated with all-cause mortality for
females, whereas for males the model included the BODE
index and Charlson comorbidity score. The model explained a
higher percentage of the variance for females compared with
males (32.5 versus 16.8%; p,0.001). The BODE index was also
the only variable associated with respiratory mortality for both
sexes. This model explained a higher percentage of the
variance (46%) in females.
Receiver operating curves analysis
The discriminatory value of the BODE index in relation to
survival was significantly higher than that of FEV1% in both
sexes (fig. 3).
DISCUSSION
The present study has two important findings. First, females
with similar degrees of airflow obstruction and BODE index
have better survival over time than males. Secondly, the BODE
index predicts all-cause and respiratory mortality as well in
females as in males.
In population-based studies, females live longer than males
[30–32]. Recent epidemiological studies suggest an increased
mortality rate in females with COPD [33, 34]. However, there
are very few clinical studies attempting to determine sex
related differences in COPD survival adjusting for variables
known to predict outcome. Four previous studies on highly
selected patients with chronic respiratory failure and hypox-
aemia have specifically addressed mortality differences
between males and females. Three studies [16–18] indicated
that females with COPD have a better prognosis than males,
whereas one concluded the opposite [19]. MIYAMOTO et al. [16]
studied 9,759 patients with COPD, tuberculosis sequelae or
chronic interstitial pneumonia receiving long-term oxygen
therapy (LTOT) and reported a better survival for females than
males. CROCKETT et al. [17] studied a population of 505 COPD
patients (256 females) also receiving LTOT and confirmed the
previous findings. CROCKETT et al. [17] also reported that the
prognostic factors for females (age, FEV1, BMI and comorbid-
ities) were different from those of males (only BMI). Recently,
FRANKLIN et al. [18] followed 5,689 COPD patients (2,894
females) on LTOT and, after adjusting by age, also found a
better survival in females. Interestingly, FRANKLIN et al. [18]
noted that the incidence and prevalence for LTOT increased
more rapidly in females than males. All of these reports
supported a better survival in females than in males with
severe COPD. In contrast, MACHADO et al. [19] assessed 435
patients (184 females) with severe COPD receiving LTOT and
followed them over time. Surprisingly, the risk of death,
whether adjusted by age, smoking history, arterial oxygen
tension, FEV1 and BMI, was higher in females than in males.
The current results support a better survival of females
compared to males with similar baseline severity of airflow
obstruction or BODE.
There are important differences between the current and
previous studies. First, while the previous studies included
TABLE 5 Multivariate analysis including all variables
significant in the univariate analysis#
Outcome Variable HR 95% CI p-value
All-cause mortality
Females BODE 2.26 1.6–3.2 ,0.001
Males BODE 1.4 1.21–1.61 ,0.001
Charlson 1.19 1.03–1.37 0.032
Respiratory mortality
Females BODE 3.17 1.87–5.36 ,0.001
Males BODE 1.53 1.30–1.79 ,0.001
HR: hazard ratio; CI: confidence interval; BODE: body mass index (BMI), airflow
obstruction, dyspnoea, exercise capacity. #: analysis adjusted for age, pack-yrs
history, comorbidity and BMI.
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FIGURE 3. Receiver operating curves for all-cause mortality for the BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index (–––––) and
percentage forced expiratory volume in one second (FEV1%; - - - - -) in a) females and b) males with chronic obstructive pulmonary disease. The discriminative value of the
BODE index was higher than the discriminative value for FEV1% (????????) in both females and males. BODE: a) area 0.82, 95% confidence interval (CI) 0.74–0.86, SE 0.030; b)
area 0.80, 95% CI 0.73–0.84, SE 0.029. FEV1: a) area 0.69, 95% CI 0.62–0.77, SE 0.038; b) area 0.66, 95% CI 0.60–0.73, SE 0.034.
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patients with severe disease and chronic respiratory failure
requiring LTOT, the current study is based on a well pheno-
typed population of patients with a wide range of COPD
severity. The majority of patients included in the current study
had either mild or moderate COPD (stage I or II in the GOLD
classification) and were in Q1 and Q2 of the BODE index.
Secondly, previous studies adjusted the results by some
prognostic factors but not by the best predictor of mortality
in COPD, i.e. the BODE index [22].
In the current study, males were slightly older, had a longer
smoking history and a higher comorbidity score than females;
all factors that may play a role in the survival difference
between males and females. However, the difference in
mortality persisted after adjusting for these factors (tables 4
and 5), which suggests the presence of other reasons not
detected by the Charlson comorbidity index. This suggests a
need to develop a better index that can more precisely capture
the comorbidities of importance in patients with COPD.
Although the impact of comorbidities in the clinical course of
COPD was described almost 10 yrs ago [35], it is only now that
it has begun to receive specific attention [36]. In the present
study, comorbidities seemed to impact only in all-cause
mortality in males (tables 4 and 5). Surprisingly, when
respiratory mortality was compared by BODE quartiles, a
higher mortality was found in males than in females only in
the most severe quartile. This is an important finding that
reproduces those reported by CELLI et al. [22] and INCALZI et al.
[35], which suggests that the course of COPD per se, may be
similar in females and males as the COPD progresses and that
the differences in overall survival in males with more severe
COPD could possibly be due to added comorbidity. This could
also explain the differences in all-cause mortality between both
sexes. From the present study it is difficult to determine exactly
if the type of comorbidity is the same for males and females
because the overall Charlson comorbidity score, although
higher in males, failed to reach statistical significance. It could
be speculated that the increased mortality in males is due to a
higher prevalence of cardiovascular disease and lung cancer in
this sex, but this remains to be explored.
The multidimensional BODE index [22] was developed and
validated in a cohort of patients with COPD that consisted
primarily of males (95%). BODE was a better predictor of
outcome than the GOLD stages in two different studies [37,
38]. The current study expands these observations showing
that the BODE index predicts survival in females as well as in
males and that for both sexes the BODE index is a better
predictor than FEV1%. The multivariate analysis showed that
BODE index is an excellent predictor of all-cause and respir-
atory mortality for females and males. Interestingly, it has been
previously reported that the relative weight of each individual
component of the BODE index differs between males and
females [39]. However, the composite index prognosticates
with similar power in both sexes. This finding makes the
BODE index very useful when comparing sex-related out-
comes because it provides a global comprehensive overview
not provided by the individual domains. The current data
supports the usefulness of the BODE index as a tool to assess
the multidimensional expression of the disease irrespective
of sex.
The current findings have some clinical implications in the
management of females with COPD. Given the better survival
for females with the higher BODE scores (7–10), interventions
such as lung volume reduction surgery or lung transplantation
could be timed differently. For example, if a COPD patient in
BODE Q4 is evaluated for lung transplant, the evaluating team
should be aware that the 3-yr survival time for females is
,50% while only 20% for males. Likewise, a more aggressive
detection and treatment of comorbidities is suggested in males,
as they are likely to be the cause of death in this sex.
There were some limitations to this study. First, the current
study patients were enrolled in pulmonary clinics in Europe,
Latin America and the USA; therefore, the findings may not be
totally applicable to the entire worldwide COPD population.
However, this study represents the largest study of well
phenotyped females with COPD using the most important
prognostic factors for the disease. Secondly, although the
authors were careful to match male and female patients
enrolled during the same study period, one cannot be entirely
sure that differences in mortality are not due to treatment
differences. However, none of the currently available treat-
ments for the disease have shown to be sex sensitive [40].
Thirdly, the exact proportion of the causes of death may not be
accurate since it was obtained from review of the medical
records or death certificates. This is a known limitation of
many COPD survival studies [41]. However, the primary
outcome of the present study was to investigate sex differences
in all-cause mortality, a very hard end-point. Fourthly, the
present authors acknowledge the important impact that
exacerbations have in mortality of COPD patients.
Unfortunately, the authors did not have precise information
in some study sites, thus preventing a robust analysis of the
data. Finally, depression and anxiety were not evaluated in this
cohort. However, these tend to be worse in females [42] and, if
anything, would impact more on females than males.
In summary, the present study shows that all-cause and
respiratory mortality are significantly lower in females than in
males with similar chronic obstructive pulmonary disease
severity. It also shows that the BODE (body mass index,
airflow obstruction, dyspnoea, exercise capacity) index is as
good a predictor of mortality in females with chronic
obstructive pulmonary disease as in males with chronic
obstructive pulmonary disease. Larger studies are needed to
further investigate sex influence in the expression of chronic
obstructive pulmonary disease.
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